Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer

Hanna Rahbek Mortensen; Jens Overgaard; Lena Specht; Marie Overgaard; Jørgen Bjerregaard Johansen; Jan F Evensen; Lisbeth Juel Andersen; Elo Andersen; Cai Grau

doi:10.1016/j.radonc.2012.01.002

Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer

Hanna Rahbek Mortensen, Jens Overgaard, Lena Specht, Marie Overgaard, Jørgen Bjerregaard Johansen, Jan F Evensen, Lisbeth Juel Andersen, Elo Andersen, Cai Grau

67 Citationer (Scopus)

Abstract

BACKGROUND AND PURPOSE: The aim of this report was to describe the incidence and prevalence of acute and late morbidity in the DAHANCA 6&7 multicentre randomised trial with accelerated radiotherapy for squamous cell carcinoma of the head and neck. MATERIALS AND METHODS: The DAHANCA 6&7 study included 1476 patients eligible for primary radiotherapy alone. Patients were randomised between five or six weekly fractions of conventional radiotherapy. The prescribed dose was 66-68Gy in 33-34 fractions. All patients were seen weekly during treatment and at regular intervals after completion where detailed morbidity recording was done. Reports from 1468 patients were available for analysis of treatment related morbidity. RESULTS: Accelerated radiotherapy caused a significant (p

Originalsprog	Engelsk
Tidsskrift	Radiotherapy & Oncology
Vol/bind	103
Udgave nummer	1
Sider (fra-til)	69-75
ISSN	0167-8140
DOI	https://doi.org/10.1016/j.radonc.2012.01.002
Status	Udgivet - apr. 2012

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1016/j.radonc.2012.01.002

Citationsformater

Mortensen, H. R., Overgaard, J., Specht, L., Overgaard, M., Johansen, J. B., Evensen, J. F., Andersen, L. J., Andersen, E., & Grau, C. (2012). Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. Radiotherapy & Oncology, 103(1), 69-75. https://doi.org/10.1016/j.radonc.2012.01.002

Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. / Mortensen, Hanna Rahbek; Overgaard, Jens; Specht, Lena et al.

I: Radiotherapy & Oncology, Bind 103, Nr. 1, 04.2012, s. 69-75.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Mortensen, HR, Overgaard, J, Specht, L, Overgaard, M, Johansen, JB, Evensen, JF, Andersen, LJ, Andersen, E & Grau, C 2012, 'Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer', Radiotherapy & Oncology, bind 103, nr. 1, s. 69-75. https://doi.org/10.1016/j.radonc.2012.01.002

@article{9257171c65164cfa882dc5e399216bef,

title = "Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer",

abstract = "BACKGROUND AND PURPOSE: The aim of this report was to describe the incidence and prevalence of acute and late morbidity in the DAHANCA 6&7 multicentre randomised trial with accelerated radiotherapy for squamous cell carcinoma of the head and neck. MATERIALS AND METHODS: The DAHANCA 6&7 study included 1476 patients eligible for primary radiotherapy alone. Patients were randomised between five or six weekly fractions of conventional radiotherapy. The prescribed dose was 66-68Gy in 33-34 fractions. All patients were seen weekly during treatment and at regular intervals after completion where detailed morbidity recording was done. Reports from 1468 patients were available for analysis of treatment related morbidity. RESULTS: Accelerated radiotherapy caused a significant (p",

author = "Mortensen, {Hanna Rahbek} and Jens Overgaard and Lena Specht and Marie Overgaard and Johansen, {J{\o}rgen Bjerregaard} and Evensen, {Jan F} and Andersen, {Lisbeth Juel} and Elo Andersen and Cai Grau",

year = "2012",

month = apr,

doi = "10.1016/j.radonc.2012.01.002",

language = "English",

volume = "103",

pages = "69--75",

journal = "Radiotherapy & Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer

AU - Mortensen, Hanna Rahbek

AU - Overgaard, Jens

AU - Specht, Lena

AU - Overgaard, Marie

AU - Johansen, Jørgen Bjerregaard

AU - Evensen, Jan F

AU - Andersen, Lisbeth Juel

AU - Andersen, Elo

AU - Grau, Cai

PY - 2012/4

Y1 - 2012/4

N2 - BACKGROUND AND PURPOSE: The aim of this report was to describe the incidence and prevalence of acute and late morbidity in the DAHANCA 6&7 multicentre randomised trial with accelerated radiotherapy for squamous cell carcinoma of the head and neck. MATERIALS AND METHODS: The DAHANCA 6&7 study included 1476 patients eligible for primary radiotherapy alone. Patients were randomised between five or six weekly fractions of conventional radiotherapy. The prescribed dose was 66-68Gy in 33-34 fractions. All patients were seen weekly during treatment and at regular intervals after completion where detailed morbidity recording was done. Reports from 1468 patients were available for analysis of treatment related morbidity. RESULTS: Accelerated radiotherapy caused a significant (p

AB - BACKGROUND AND PURPOSE: The aim of this report was to describe the incidence and prevalence of acute and late morbidity in the DAHANCA 6&7 multicentre randomised trial with accelerated radiotherapy for squamous cell carcinoma of the head and neck. MATERIALS AND METHODS: The DAHANCA 6&7 study included 1476 patients eligible for primary radiotherapy alone. Patients were randomised between five or six weekly fractions of conventional radiotherapy. The prescribed dose was 66-68Gy in 33-34 fractions. All patients were seen weekly during treatment and at regular intervals after completion where detailed morbidity recording was done. Reports from 1468 patients were available for analysis of treatment related morbidity. RESULTS: Accelerated radiotherapy caused a significant (p

U2 - 10.1016/j.radonc.2012.01.002

DO - 10.1016/j.radonc.2012.01.002

M3 - Journal article

C2 - 22398313

SN - 0167-8140

VL - 103

SP - 69

EP - 75

JO - Radiotherapy & Oncology

JF - Radiotherapy & Oncology

IS - 1

ER -

Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater